Literature DB >> 1682447

The site of inversion of R(-)-ibuprofen: studies using rat in-situ isolated perfused intestine/liver preparations.

P Jeffrey1, G T Tucker, A Bye, H K Crewe, P A Wright.   

Abstract

The site of metabolic inversion of R(-)-ibuprofen to the pharmacologically active S(+)-enantiomer has been investigated using an array of in-situ rat perfused organ preparations allowing vascular perfusion (55-60 min) of the separate or combined intestine and liver. After addition of R(-)-ibuprofen (20 mg kg-1 body weight) to the closed (static) lumen of isolated 25 cm lengths of duodenum, jejunum or ileum, and single-pass vascular perfusion, both isomers were measured in the lumen and in vascular perfusate plasma (mean plasma AUC values (+/- s.d., micrograms mL-1 min, n = 5) R(-)-ibuprofen: 1669 +/- 115 (duodenum), 1687 +/- 203 (jejunum), 2061 +/- 188 (ileum); S(+)-ibuprofen: 23 +/- 6 (duodenum), 14 +/- 5 (jejunum), 26 +/- 1 (ileum]. Addition of the same dose of S(+)-ibuprofen to the jejunum (n = 5) resulted in AUC values of 1864 +/- 238 for S(+)-ibuprofen and 6 +/- 3 for R(-)-ibuprofen. After addition of R(-)-ibuprofen (30 micrograms mL-1) to the recirculating vascular perfusate (100 mL) of the entire small intestine (n = 6) AUC values were 1647 +/- 34 for R(-)-ibuprofen and 13 +/- 3 for S(-)-ibuprofen. The same dose of R(-)-ibuprofen to combined intestine/liver (n = 6) and liver only preparations (n = 6) gave AUC values of 1011 +/- 25 and 1021 +/- 49 for R(-)-ibuprofen and 220 +/- 28 and 238 +/- 22 for S(+)-ibuprofen, respectively. In all experiments, except those involving perfusion of the combined intestine/liver and the liver, the concentrations of the isomer opposite to that administered could be accounted for solely by the level of enantiomeric impurity (1.3% for R(-)-ibuprofen and 0.6% for S(+)-ibuprofen). We conclude that inversion of R(-)-ibuprofen to the S(+) antipode occurs in the liver but does not occur on either mucosal or serosal sides of the small intestine of the rat.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682447     DOI: 10.1111/j.2042-7158.1991.tb03464.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  SI units--common sense not dogma is needed.

Authors:  R J Flanagan
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

2.  Chiral inversion of (R)-ketoprofen: influence of age and differing physiological status in dairy cattle.

Authors:  L Igarza; A Soraci; N Auza; H Zeballos
Journal:  Vet Res Commun       Date:  2002-01       Impact factor: 2.459

Review 3.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

4.  Chiral inversion of (R)-(-)-fenoprofen in guinea-pigs pretreated with clofibrate.

Authors:  M F San Martín; A Soraci; F Fogel; O Tapia; S Islas
Journal:  Vet Res Commun       Date:  2002-06       Impact factor: 2.459

5.  Involvement of the rat gut epithelial and muscular layer, and microflora in chiral inversion and acyl-glucuronidation of R-fenoprofen.

Authors:  S Sattari; F Jamali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Apr-Jun       Impact factor: 2.569

Review 6.  Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations.

Authors:  Anna Gliszczyńska; Elena Sánchez-López
Journal:  Pharmaceutics       Date:  2021-03-19       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.